NICE green-lights 5 meds, with discounts turning the tide on PCSK9, Novartis drugs


England’s cost watchdogs can often be stingy when it comes to handing out go-aheads to drugmakers. But discounts from pharma had them feeling generous Wednesday.

The National Institute for Heath and Care Excellence (NICE) published new guidelines backing National Health Service use of 5 meds, verdicts that will benefit Novartis ($NVS), AbbVie ($ABBV), Sanofi ($SNY) and Amgen ($AMGN).

The latter two companies both managed about-faces from NICE, which had earlier turned down their pricey PCSK9 meds--dubbed Praluent and Repatha, respectively. Back in May, though, the body had signaled that it would be willing to reverse course, provided the drugmakers lowered prices to reduce the dramatic gap between their £4,000-per-patient-per-year cost and the £350 sticker on Merck & Co.'s ($MRK) cholesterol fighter Zetia. 


The 13th Annual Digital Pharma East

Digital Pharma East returns to the Pennsylvania Convention Center September 17–20, bringing together over 1000 attendees from biotech and pharma, to better understand how to present business plans, justify budget and innovation, and de-risk proposals getting shut down — essentially, understand how they can return to the office and become champions for their internal digital needs. Join us and save 15% on standard rates when you register with Discount Code DPE19Fierce.

Novartis also managed a NICE turnaround, scoring a nod for targeted lung cancer therapy Zykadia in adults with ALK-positive non-small-cell lung cancer who hadn't been treated with Pfizer’s ($PFE) Xalkori. The second piece of good news for the Swiss pharma giant was a NICE endorsement for melanoma therapy Mekinist, to be used in tandem with Novartis’ Tafinlar.

The endorsements will boost Novartis’ oncology unit, which has been a strong focus for the company since the multibillion-dollar asset swap that brought GlaxoSmithKline’s ($GSK) oncology portfolio--containing Tafinlar and Mekinist, among other assets--to Basel.

Rounding things out was AbbVie’s Humira, which nabbed a favorable opinion in active moderate to severe hidradenitis. That painful skin condition is just one of many diseases Humira boasts approval to treat, which has helped it become the world’s best-selling drug.

- see NICE's guidance for PraluentRepathaZykadiaMekinist and Humira

Related Articles:
NICE gives tentative broad approval to both Repatha, Praluent
NICE, in reversal, OKs Amgen's Repatha while snubbing Sanofi and Regeneron's Praluent
Novartis’ new melanoma combo gains NICE nod

Suggested Articles

Bristol-Myers Squibb is out to expand the pool of colorectal cancer patients it can treat with Opdivo—and it’s bringing in Bayer to help.

When AstraZeneca sold its Avlon, England plant in 2016, it thought its liabilities were over. Former employees said the drugmaker broke its promises.

Pharmacy chain Rite Aid has partnered with Google to have their drug recycling stations easily searchable on Google Maps.